Direct Oral Anticoagulant Drugs in Dental Clinical Practice
, , , , , , , et
30 sept. 2017
À propos de cet article
Publié en ligne: 30 sept. 2017
Pages: 20 - 27
Reçu: 09 mars 2017
Accepté: 13 mai 2017
DOI: https://doi.org/10.1515/acm-2017-0008
Mots clés
© by J. Stasko
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
The direct oral anticoagulant drugs (DOAC) are generally safe and effective in several clinical settings including acute venous thromboembolic disease, prophylaxis in the postoperative setting, prevention of thromboembolism in patients with non-valvular atrial fibrillation, and in the management of acute coronary syndrome. The relatively short half-life, rapid onset of action, and predictable pharmacokinetics should simplify periprocedural use of the DOAC. The aim of this work is to propose and summarize periprocedural management of patients treated with the DOAC in dental practice and to inform about the principal specifications of this treatment.